Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar
- PMID: 19623100
- DOI: 10.1097/MCG.0b013e31815bd749
Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar
Abstract
Background: The implications of the Rome III recommendations to change the irritable bowel syndrome (IBS) subtype criteria for stool pattern are unknown.
Aim: (1) Determine the level of agreement between Rome II and Rome III subtypes and (2) compare the behaviors of Rome II and Rome III subtypes over time.
Methods: Female patients (n=148) with Rome II defined IBS were prospectively tracked over 5 consecutive 3-month periods. At baseline, bowel habit reports on questionnaires were used to subclassify patients into Rome II and Rome III subtypes. Over the subsequent 15 months, bowel habit reports on diary cards were used to subclassify patients based on previously derived surrogate criteria into Rome II and Rome III IBS subtypes.
Results: The level of agreement between Rome II and Rome III subtype assignments was quite high (86.5%; kappa 0.79). The behavior of Rome II and Rome III subtypes over time was also similar in terms of subtype prevalence, subtype stability, and the proportion of subjects who met criteria for alternating irritable bowel syndrome.
Conclusions: Rome II and Rome III IBS subtypes are in high agreement and behave similarly over time. Therefore, studies that used Rome II subtype criteria and studies that will use Rome III criteria will define comparable populations.
Similar articles
-
Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III.Aliment Pharmacol Ther. 2007 Sep 15;26(6):953-61. doi: 10.1111/j.1365-2036.2007.03422.x. Aliment Pharmacol Ther. 2007. PMID: 17767480
-
Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study.J Gastroenterol Hepatol. 2012 Apr;27(4):760-5. doi: 10.1111/j.1440-1746.2011.06930.x. J Gastroenterol Hepatol. 2012. PMID: 21929652
-
Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification.Aliment Pharmacol Ther. 2012 Feb;35(3):350-9. doi: 10.1111/j.1365-2036.2011.04948.x. Epub 2011 Dec 18. Aliment Pharmacol Ther. 2012. PMID: 22176384
-
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20. Lancet Gastroenterol Hepatol. 2020. PMID: 32702295
-
Irritable Bowel Syndrome Subtypes: New Names for Old Medical Conditions.Dig Dis. 2020;38(2):122-127. doi: 10.1159/000505287. Epub 2019 Dec 18. Dig Dis. 2020. PMID: 31851972 Review.
Cited by
-
Blastocystis subtypes isolated from irritable bowel syndrome patients and co-infection with Helicobacter pylori.Parasitol Res. 2018 Jan;117(1):127-137. doi: 10.1007/s00436-017-5679-4. Epub 2017 Nov 14. Parasitol Res. 2018. PMID: 29138961
-
Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials.Medicine (Baltimore). 2016 Jan;95(4):e2534. doi: 10.1097/MD.0000000000002534. Medicine (Baltimore). 2016. PMID: 26825893 Free PMC article. Review.
-
Type of Rectal Barostat Protocol Affects Classification of Hypersensitivity and Prediction of Symptom Severity in Irritable Bowel Syndrome.J Neurogastroenterol Motil. 2022 Oct 30;28(4):630-641. doi: 10.5056/jnm21214. J Neurogastroenterol Motil. 2022. PMID: 36250370 Free PMC article.
-
IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment.Am J Gastroenterol. 2012 Feb;107(2):286-95. doi: 10.1038/ajg.2011.358. Epub 2011 Nov 8. Am J Gastroenterol. 2012. PMID: 22068664 Free PMC article.
-
Current insights in to the pathophysiology of Irritable Bowel Syndrome.Gut Pathog. 2010 May 13;2(1):3. doi: 10.1186/1757-4749-2-3. Gut Pathog. 2010. PMID: 20465787 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous